NeOnc Technologies Holdings, Inc. Announces Private Placement of Common Stock and Warrants

NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company based in Calabasas, California, has filed a Form 8-K to announce a significant private placement of equity securities. The transaction, which closed on February 24, 2026, is detailed in a Securities Purchase Agreement, representing a strategic move to raise capital for the company.

Key Points from the Filing

• Unregistered Sale of Equity Securities: The company sold shares of its common stock, par value \$0.0001 per share, along with five-year warrants to purchase additional shares of common stock. These securities were issued in a private placement to select accredited investors.
• Details of the Offering:
  • Each investor agreed to purchase a specific number of shares and warrants as outlined in Exhibit A of the agreement. The sale price per share was \$7.20, with the total number of shares and warrants matching the amount purchased by each investor.
  • The securities sold and issued were not registered under the Securities Act of 1933 and are “restricted securities.” They cannot be resold unless registered or an exemption is available.
• Warrant Exercise Terms: The warrants allow the holder to purchase shares at a set exercise price (to be specified in the warrant), for a period of five years from the date of issuance. The formula for determining the number of shares to be issued upon exercise is clearly specified in the agreement.
• Registration Rights:
  • NeOnc Technologies has agreed to file a registration statement on Form S-1 with the SEC as soon as possible, but no later than 10 days following the filing of its Annual Report on Form 10-K for the year ended December 31, 2025.
  • This registration statement will cover the resale of both the shares and warrant shares, enabling investors to trade these securities freely once the statement is declared effective.
  • The company will bear all registration-related expenses, except for underwriting discounts and commissions, which are the responsibility of the selling shareholder.
• Indemnification Provisions: The company has agreed to indemnify investors against losses arising from misstatements or omissions in the registration statement, while investors will indemnify the company for misstatements they may provide for inclusion in the filing.
• Conditions to Closing:
  • Investors must receive evidence of electronic transfer of shares and completed warrants.
  • The company must receive wire transfer of funds in consideration for the securities issued.
• Emerging Growth Company Status: The filing confirms that NeOnc Technologies is an emerging growth company as defined under the relevant SEC rules.
• Disclosure of Non-Public Information: The company specifically represents that it has not disclosed material, non-public information to investors in connection with this transaction, which is important for compliance with insider trading regulations.

Potentially Price Sensitive Information & Implications for Shareholders

• Capital Raise and Dilution: The private placement provides NeOnc Technologies with new capital, which could be used to fund ongoing operations, clinical trials, or other strategic initiatives. However, the issuance of new shares and warrants will dilute existing shareholders, which may impact the share price upon conversion or exercise of the warrants.
• Future Liquidity: The agreement obligates NeOnc Technologies to register the resale of the shares and warrant shares, potentially adding significant tradable volume to the market once the restriction is lifted. This could affect supply-demand dynamics for the stock.
• Potential for Share Price Volatility: The details of the private placement, including the exercise price of warrants and the timing of the registration statement effectiveness, could lead to increased trading activity and volatility as investors anticipate resale of the new shares.

Additional Details

• Accredited Investors: Only accredited investors participated in the offering, and all representations and warranties of both the company and investors are detailed in the agreement.
• Blue Sky Compliance: The company will handle necessary blue sky filings to ensure the securities can be sold in the required states.
• Plan of Distribution: The registered shares may be sold on the Nasdaq or other trading platforms, over-the-counter, through block trades, or via other means as detailed in the registration statement.

What Should Shareholders Watch?

• Watch for the filing and effectiveness of the S-1 resale registration statement, which will signal when these shares and warrant shares may become freely tradable.
• Monitor for any updates on the use of proceeds from this capital raise, which may be announced in subsequent filings or press releases.
• Be alert to potential dilution from warrant exercises and the impact on overall share count and earnings per share metrics.

Disclaimer: This article is based on a reading and analysis of NeOnc Technologies Holdings, Inc.’s Form 8-K and related exhibits, as filed with the U.S. Securities and Exchange Commission. It is intended for informational purposes only and does not constitute investment advice. Investors should review the original filings and consult with their financial advisors before making investment decisions. The author and publisher accept no liability for actions taken based on this information.

View NEONC TECHNOLOGIES HOLDINGS, INC. Historical chart here